Healthcare Review: Edwards Lifesciences, Allergan, Questcor Pharmaceuticals, Navidea Biopharmaceuticals, Repros Therapeutics Print E-mail
By Staff and Wire Reports   
Wednesday, 21 August 2013 18:29
U.S. stocks fell, with the Dow Jones Industrial Average on track for its longest slump in 13 months, as the Federal Reserve’s July meeting minutes showed officials support the timeline for reducing stimulus. Fed officials were “broadly comfortable” with Chairman Ben S. Bernanke’s plan to start reducing bond buying later this year if the economy improves, with a few saying tapering might be needed soon, minutes of their last meeting show.

Edwards Lifesciences (EW) says Japan has given the go-ahead for reimbursement costs of its transcatheter aortic heart value.The reimbursement is scheduled to go into effect on October 1.The rate has been set at ¥4.53M (approximately $46K) for when the valve used in the treatment of patients with severe symptomatic aortic stenosis, and covers the cost of the device as well as taxes, certain hospital fees and distribution expenses.

Allergan (AGN) is out defending Restasis in the face of FDA draft guidance issued in June which said in vitro analysis would be sufficient to establish bioequivalence.AGN "respectfully" disagrees, calling the regulator's proposal "unsound both scientifically and legally."In short, AGN wants generics tested in patients rather than just in the lab, which would fend-off competition for the drug which generated nearly $800M in revenue in 2012.

Questcor Pharmaceuticals (QCOR) is up 4.9%.Bank of America upgrades the shares to Buy from Neutral.Price target raised to $80 (from $58), representing a 23% upside from Tuesday's close.On Monday, Oppenheimer raised its price target on the shares to $73.

Navidea Biopharmaceuticals (NAVB) signs an agreement for Siemens Petnet Solutions (SI) to manufacture Navidea's NAV4694 PET imaging agent, which is in Phase II and Phase III trials for evaluating patients with signs of Alzheimers disease and mild cognitive impairment.Siemens Petnet Solutions operates the world's largest network of PET (positron emission tomography) radiopharmaceutical drug manufacturing facilities and dispensing nuclear pharmacies.

Repros Therapeutics (RPRX) reports six-month interim results from a study of "Androxal treatment of secondary hypogonadal men and its effect on bone mineral density."No bone loss was observed compared to placebo.Some improvement in bone mineral density was observed in the Androxal group.Topline, 12-month results are due in Q2 2014.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter